Project Grant 5920325001F2

This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...

Federal Project Grant Summary Award Overview Loyola University of Chicago's Health Sciences Campus received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 25, 2025, with a completion date of May 31, 2027. The research initiative focuses on developing novel antibodies targeting autoreactive B cells as a potential therapeutic intervention for systemic lupus...

Federal Project Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $781,718 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2025 through May 31, 2030. The award supports the development of a novel T cell-based vaccine designed to prevent dengue virus (DENV) and Zika virus (ZIKV) infection while avoiding antibody-dependent enhancement...

Federal Grant Award Summary Immunogenik, Inc. received a $398,997 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on June 9, 2025, with completion targeted for May 31, 2027. The company is developing a clinical-grade humanized antibody (hu-ALAIR1) that targets Leukocyte-Associated Immunoglobulin-Like Receptor 1 (LAIR1/CD305), a novel immune checkpoint expressed on tumor-associated macrophages. The therapeutic approach aims to...

Federal Grant Award Summary Yale University received a $251,563 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 20, 2026, with a completion date of January 31, 2028. The grant funds a longitudinal cohort study assessing the immunogenicity of QDENGA (TAK-003), Takeda's dengue vaccine, in real-world conditions. The research deliverables include comprehensive immunological...

Federal Project Grant Award Summary The La Jolla Institute for Immunology received a $890,877 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026, through January 31, 2031. This five-year research initiative focuses on elucidating the immunoregulatory mechanisms of Interleukin-1 Receptor 8 (IL-1R8) and developing novel therapeutic strategies targeting this...

Federal Grant Award Summary The University of Alabama at Birmingham received a $409,750 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 9, 2026, with completion targeted for January 31, 2028. This research project aims to identify and develop immunoregulatory metabolic signals that suppress T-helper cell-dependent B cell (T-BET+ B cell) development in systemic lupus...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tulane University $765,000 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 20, 2025, for a project titled "Role of TXLNA in Cytosolic DNA-Mediated Innate Immunity." The award, with a completion date of May 31, 2030, will fund basic science research investigating the function of taxilin alpha (TXLNA) protein in regulating innate immune responses to...

Cooperative Agreement Summary Boston Children's Hospital, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), received a cooperative agreement award of $1.67 million on September 25, 2025, to conduct a Phase 1 clinical study evaluating a novel messenger RNA (mRNA)-lipid nanoparticle (LNP)-based SARS-CoV-2 vaccine incorporating controlled biodistribution technology and interleukin-12...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded La Jolla Institute for Immunology a $476,436 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 5, 2026 through January 31, 2028. This research initiative focuses on defining the function and regulation of ILRUN (Interferon Lambda-Related Ras Kinase), a novel systemic lupus erythematosus (SLE) susceptibility gene in T cells. The...